FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098407557> ?p ?o ?g. }

• W2098407557 endingPage "2300" @default.
• W2098407557 startingPage "2292" @default.
• W2098407557 abstract "Fulvestrant is known to promote the degradation of the estrogen receptor (ER) in the nucleus. However, fulvestrant also promotes the aggregation of the newly synthesized ER in the cytoplasm. Accumulation of protein aggregates leads to cell death but this effect is limited as a result of their elimination by the proteasome. We tested whether combining fulvestrant with the proteasome inhibitor, bortezomib, could enhance the accumulation of ER aggregates and cause apoptotic cell death.The rate of aggregation of the ER was monitored in ER(+) breast cancer cells lines, T47D, ZR-75.1, BT474, MDA-MB-361, MCF-7, fulvestrant resistance MCF-7, and tamoxifen-resistant T47D-cyclin D1 cells. Activation of the unfolded protein response, apoptosis, and metabolic rate were also monitored in these cell lines following treatment with fulvestrant, bortezomib, or bortezomib in combination with fulvestrant.We found that bortezomib enhances the fulvestrant-mediated aggregation of the ER in the cytoplasm without blocking the degradation of the ER in the nucleus. Further, these aggregates activate a sustained unfolded protein response leading to apoptotic cell death. Further, we show that the combination induced tumor regression in a breast cancer mouse model of tamoxifen resistance.Adding bortezomib to fulvestrant enhances its efficacy by taking advantage of the unique ability of fulvestrant to promote cytoplasmic aggregates of the ER. As this effect of fulvestrant is independent of the transcriptional activity of the ER, these results suggest that this novel combination may be effective in breast cancers that are ER(+) but estrogen independent." @default.
• W2098407557 created "2016-06-24" @default.
• W2098407557 creator A5002131310 @default.
• W2098407557 creator A5004309619 @default.
• W2098407557 creator A5017065646 @default.
• W2098407557 creator A5021959959 @default.
• W2098407557 creator A5033039574 @default.
• W2098407557 creator A5048693408 @default.
• W2098407557 creator A5050437171 @default.
• W2098407557 creator A5067097797 @default.
• W2098407557 date "2011-04-14" @default.
• W2098407557 modified "2023-10-18" @default.
• W2098407557 title "Bortezomib Enhances the Efficacy of Fulvestrant by Amplifying the Aggregation of the Estrogen Receptor, Which Leads to a Proapoptotic Unfolded Protein Response" @default.
• W2098407557 cites W1491569850 @default.
• W2098407557 cites W1967949926 @default.
• W2098407557 cites W1991100787 @default.
• W2098407557 cites W2057518766 @default.
• W2098407557 cites W2058906289 @default.
• W2098407557 cites W2064122617 @default.
• W2098407557 cites W2065346432 @default.
• W2098407557 cites W2066765509 @default.
• W2098407557 cites W2072714194 @default.
• W2098407557 cites W2077247713 @default.
• W2098407557 cites W2079791855 @default.
• W2098407557 cites W2102217018 @default.
• W2098407557 cites W2104599023 @default.
• W2098407557 cites W2110700838 @default.
• W2098407557 cites W2112018984 @default.
• W2098407557 cites W2115205812 @default.
• W2098407557 cites W2118305948 @default.
• W2098407557 cites W2122969246 @default.
• W2098407557 cites W2125798501 @default.
• W2098407557 cites W2139152149 @default.
• W2098407557 cites W2146712472 @default.
• W2098407557 cites W2147576659 @default.
• W2098407557 cites W2147673480 @default.
• W2098407557 cites W2148449686 @default.
• W2098407557 cites W2158892689 @default.
• W2098407557 cites W4296231862 @default.
• W2098407557 doi "https://doi.org/10.1158/1078-0432.ccr-10-1745" @default.
• W2098407557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3232249" @default.
• W2098407557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21292820" @default.
• W2098407557 hasPublicationYear "2011" @default.
• W2098407557 type Work @default.
• W2098407557 sameAs 2098407557 @default.
• W2098407557 citedByCount "31" @default.
• W2098407557 countsByYear W20984075572012 @default.
• W2098407557 countsByYear W20984075572013 @default.
• W2098407557 countsByYear W20984075572014 @default.
• W2098407557 countsByYear W20984075572015 @default.
• W2098407557 countsByYear W20984075572016 @default.
• W2098407557 countsByYear W20984075572017 @default.
• W2098407557 countsByYear W20984075572018 @default.
• W2098407557 countsByYear W20984075572019 @default.
• W2098407557 countsByYear W20984075572020 @default.
• W2098407557 countsByYear W20984075572021 @default.
• W2098407557 countsByYear W20984075572022 @default.
• W2098407557 countsByYear W20984075572023 @default.
• W2098407557 crossrefType "journal-article" @default.
• W2098407557 hasAuthorship W2098407557A5002131310 @default.
• W2098407557 hasAuthorship W2098407557A5004309619 @default.
• W2098407557 hasAuthorship W2098407557A5017065646 @default.
• W2098407557 hasAuthorship W2098407557A5021959959 @default.
• W2098407557 hasAuthorship W2098407557A5033039574 @default.
• W2098407557 hasAuthorship W2098407557A5048693408 @default.
• W2098407557 hasAuthorship W2098407557A5050437171 @default.
• W2098407557 hasAuthorship W2098407557A5067097797 @default.
• W2098407557 hasBestOaLocation W20984075571 @default.
• W2098407557 hasConcept C121608353 @default.
• W2098407557 hasConcept C126322002 @default.
• W2098407557 hasConcept C172313692 @default.
• W2098407557 hasConcept C185592680 @default.
• W2098407557 hasConcept C190283241 @default.
• W2098407557 hasConcept C27740335 @default.
• W2098407557 hasConcept C2776364478 @default.
• W2098407557 hasConcept C2777176818 @default.
• W2098407557 hasConcept C2777478702 @default.
• W2098407557 hasConcept C2778367456 @default.
• W2098407557 hasConcept C2780482068 @default.
• W2098407557 hasConcept C31573885 @default.
• W2098407557 hasConcept C502942594 @default.
• W2098407557 hasConcept C530470458 @default.
• W2098407557 hasConcept C55493867 @default.
• W2098407557 hasConcept C71924100 @default.
• W2098407557 hasConcept C84606932 @default.
• W2098407557 hasConcept C86803240 @default.
• W2098407557 hasConcept C96232424 @default.
• W2098407557 hasConcept C98274493 @default.
• W2098407557 hasConceptScore W2098407557C121608353 @default.
• W2098407557 hasConceptScore W2098407557C126322002 @default.
• W2098407557 hasConceptScore W2098407557C172313692 @default.
• W2098407557 hasConceptScore W2098407557C185592680 @default.
• W2098407557 hasConceptScore W2098407557C190283241 @default.
• W2098407557 hasConceptScore W2098407557C27740335 @default.
• W2098407557 hasConceptScore W2098407557C2776364478 @default.
• W2098407557 hasConceptScore W2098407557C2777176818 @default.
• W2098407557 hasConceptScore W2098407557C2777478702 @default.
• W2098407557 hasConceptScore W2098407557C2778367456 @default.

• next